Acadia Pharmaceuticals Inc.
—- Market cap
- —
- Debt
- +$306.51M
- Cash
- −$177.70M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ACAD stock price vs FSLY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FSLY's multiple
Needs FSLY P/E.
Implied fair value · at ACAD's multiple
Needs Annual EPS is negative, ACAD P/E.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ACAD FY 2025 (ended Dec 31, 2025) · FSLY FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Fastly, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.25x
0.39x
Net debt / EBITDA
Leverage against operating earnings
0.85x
-0.01x
Cash and equivalents
Liquid reserves on the balance sheet
$177.70M
$361.76M
Total debt
Interest-bearing obligations outstanding
$306.51M
$361.84M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ACAD vs SUPN
Sage Therapeutics, Inc.
ACAD vs SAGE
Jazz Pharmaceuticals plc
ACAD vs JAZZ
Alkermes plc.
ACAD vs ALKS
Harmony Biosciences Holdings, Inc.
ACAD vs HRMY
Krystal Biotech, Inc.
ACAD vs KRYS
Cloudflare, Inc.
ACAD vs NET
AKAMAI TECHNOLOGIES INC
ACAD vs AKAM
Lumen Technologies, Inc.
ACAD vs LUMN
CISCO SYSTEMS, INC.
ACAD vs CSCO
VIASAT INC
ACAD vs VSAT
Zscaler, Inc.
ACAD vs ZS
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.